Strs Ohio lowered its stake in shares of Clovis Oncology Inc (NASDAQ:CLVS) by 40.4% during the fourth quarter, Holdings Channel reports. The fund owned 3,100 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Strs Ohio’s holdings in Clovis Oncology were worth $210,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Orbimed Advisors LLC boosted its stake in shares of Clovis Oncology by 13.5% during the third quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock valued at $196,826,000 after acquiring an additional 284,300 shares during the last quarter. State Street Corp boosted its stake in shares of Clovis Oncology by 4.3% during the second quarter. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company’s stock valued at $181,966,000 after acquiring an additional 80,171 shares during the last quarter. Macquarie Group Ltd. boosted its stake in shares of Clovis Oncology by 56.0% during the third quarter. Macquarie Group Ltd. now owns 526,880 shares of the biopharmaceutical company’s stock valued at $43,415,000 after acquiring an additional 189,211 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Clovis Oncology by 45.8% during the third quarter. Westfield Capital Management Co. LP now owns 459,470 shares of the biopharmaceutical company’s stock valued at $37,860,000 after acquiring an additional 144,300 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Clovis Oncology by 16.3% during the third quarter. Pictet Asset Management Ltd. now owns 367,029 shares of the biopharmaceutical company’s stock valued at $30,243,000 after acquiring an additional 51,366 shares during the last quarter.

A number of analysts recently commented on CLVS shares. Barclays started coverage on Clovis Oncology in a research note on Monday, October 23rd. They set an “overweight” rating and a $105.00 price objective on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Clovis Oncology in a research note on Thursday, January 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $125.00 price objective on shares of Clovis Oncology in a research note on Friday, November 3rd. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research note on Tuesday, October 17th. Finally, Leerink Swann reissued an “outperform” rating and issued a $90.00 price target (down from $107.00) on shares of Clovis Oncology in a research note on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. Clovis Oncology presently has a consensus rating of “Hold” and an average target price of $90.43.

Shares of Clovis Oncology Inc (NASDAQ CLVS) opened at $53.06 on Tuesday. The stock has a market capitalization of $2,495.84, a PE ratio of -6.41 and a beta of 1.05. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94. Clovis Oncology Inc has a 52 week low of $45.42 and a 52 week high of $99.45.

In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $63.70, for a total value of $191,100.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $64.97, for a total value of $292,365.00. Following the completion of the transaction, the director now owns 21,118 shares in the company, valued at $1,372,036.46. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,000 shares of company stock worth $1,123,425. Company insiders own 12.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://theolympiareport.com/2018/02/13/strs-ohio-has-210000-position-in-clovis-oncology-inc-clvs.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.